{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T20:36:28Z","timestamp":1772138188319,"version":"3.50.1"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2023,2,21]],"date-time":"2023-02-21T00:00:00Z","timestamp":1676937600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["3R01AI152078-01S1)"],"award-info":[{"award-number":["3R01AI152078-01S1)"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["U24TR001609)"],"award-info":[{"award-number":["U24TR001609)"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["10430062010001"],"award-info":[{"award-number":["10430062010001"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill & Melinda Gates Foundation","doi-asserted-by":"publisher","award":["1OT2HL156812-01"],"award-info":[{"award-number":["1OT2HL156812-01"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill & Melinda Gates Foundation","doi-asserted-by":"publisher","award":["U24NS100659"],"award-info":[{"award-number":["U24NS100659"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill & Melinda Gates Foundation","doi-asserted-by":"publisher","award":["U24NS100655"],"award-info":[{"award-number":["U24NS100655"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["75A50120C00094"],"award-info":[{"award-number":["75A50120C00094"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012399","name":"Biomedical Advanced Research and Development Authority","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000016","name":"Department of Health and Human Services","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000016","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,6,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Outpatient monoclonal antibodies are no longer effective and antiviral treatments for coronavirus disease 2019 (COVID-19) disease remain largely unavailable in many countries worldwide. Although treatment with COVID-19 convalescent plasma (CCP) is promising, clinical trials among outpatients have shown mixed results.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted an individual participant data meta-analysis from outpatient trials to assess the overall risk reduction for all-cause hospitalizations by day 28 in transfused participants. Relevant trials were identified by searching Medline, Embase, medRxiv, World Health Organization COVID-19 Research Database, Cochrane Library, and Web of Science from January 2020 to September 2022.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Five included studies from 4 countries enrolled and transfused 2620 adult patients. Comorbidities were present in 1795 (69%). The virus neutralizing antibody dilutional titer levels ranged from 8 to 14 580 in diverse assays. One hundred sixty of 1315 (12.2%) control patients were hospitalized, versus 111 of 1305 (8.5%) CCP-treated patients, yielding a 3.7% (95% confidence interval [CI], 1.3%\u20136.0%; P = .001) absolute risk reduction and 30.1% relative risk reduction for all-cause hospitalization. The hospitalization reduction was greatest in those with both early transfusion and high titer with a 7.6% absolute risk reduction (95% CI, 4.0%\u201311.1%; P = .0001) accompanied by at 51.4% relative risk reduction. No significant reduction in hospitalization was seen with treatment &amp;gt;5 days after symptom onset or in those receiving CCP with antibody titers below the median titer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Among outpatients with COVID-19, treatment with CCP reduced the rate of all-cause hospitalization and may be most effective when given within 5 days of symptom onset and when antibody titer is higher.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/cid\/ciad088","type":"journal-article","created":{"date-parts":[[2023,2,21]],"date-time":"2023-02-21T14:41:24Z","timestamp":1676990484000},"page":"2077-2086","source":"Crossref","is-referenced-by-count":43,"title":["Coronavirus Disease 2019 Convalescent Plasma Outpatient Therapy to Prevent Outpatient Hospitalization: A Meta-Analysis of Individual Participant Data From 5 Randomized Trials"],"prefix":"10.1093","volume":"76","author":[{"given":"Adam C","family":"Levine","sequence":"first","affiliation":[{"name":"Department of Emergency Medicine, Warren Alpert Medical School of Brown University , Providence, Rhode Island , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuriko","family":"Fukuta","sequence":"additional","affiliation":[{"name":"Infectious Disease, Department of Medicine, Baylor College of Medicine , Houston, Texas , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moises A","family":"Huaman","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Cincinnati College of Medicine , Cincinnati, Ohio , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiangda","family":"Ou","sequence":"additional","affiliation":[{"name":"Division of Brain Injury Outcomes, Department of Neurology, Johns Hopkins University School of Medicine , Baltimore, Maryland , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barry R","family":"Meisenberg","sequence":"additional","affiliation":[{"name":"Department of Hematology\u2013Oncology, Anne Arundel Medical Center , Annapolis, Maryland , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bela","family":"Patel","sequence":"additional","affiliation":[{"name":"Division of Critical Care Medicine, McGovern Medical School, University of Texas Health Science Center , Houston, Texas , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James H","family":"Paxton","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, Wayne State University School of Medicine , Detroit, Michigan , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel F","family":"Hanley","sequence":"additional","affiliation":[{"name":"Division of Brain Injury Outcomes, Department of Neurology, Johns Hopkins University School of Medicine , Baltimore, Maryland , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bart J A","family":"Rijnders","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Section of Infectious Diseases and Department of Medical Microbiology and Infectious Diseases, Erasmus University Medical Center, University Medical Center , Rotterdam , The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arvind","family":"Gharbharan","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Section of Infectious Diseases and Department of Medical Microbiology and Infectious Diseases, Erasmus University Medical Center, University Medical Center , Rotterdam , The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Casper","family":"Rokx","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Section of Infectious Diseases and Department of Medical Microbiology and Infectious Diseases, Erasmus University Medical Center, University Medical Center , Rotterdam , The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaap Jan","family":"Zwaginga","sequence":"additional","affiliation":[{"name":"Department of Haematology, Leiden University Medical Centre , Leiden , The Netherlands"},{"name":"Center for Clinical Transfusion Research, Sanquin Blood Supply , Amsterdam , The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Alemany","sequence":"additional","affiliation":[{"name":"Fight Infectious Diseases Foundation, Hospital Universitari Germans Trias i Pujol , Badalona , Spain"},{"name":"Infectious Diseases Department, Hospital Universitari Germans Trias i Pujol , Badalona , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oriol","family":"Mitj\u00e0","sequence":"additional","affiliation":[{"name":"Fight Infectious Diseases Foundation, Hospital Universitari Germans Trias i Pujol , Badalona , Spain"},{"name":"Infectious Diseases Department, Hospital Universitari Germans Trias i Pujol , Badalona , Spain"},{"name":"Lihir Medical Centre, International SOS , Lihir Island , Papua New Guinea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Ouchi","sequence":"additional","affiliation":[{"name":"Fight Infectious Diseases Foundation, Hospital Universitari Germans Trias i Pujol , Badalona , Spain"},{"name":"Infectious Diseases Department, Hospital Universitari Germans Trias i Pujol , Badalona , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pere","family":"Millat-Martinez","sequence":"additional","affiliation":[{"name":"ISGlobal, Department of Infectious Diseases, Hospital Cl\u00ednic, Universitat de Barcelona , Barcelona , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valerie","family":"Durkalski-Mauldin","sequence":"additional","affiliation":[{"name":"Department of Public Health Sciences, Medical University of South Carolina , Charleston, South Carolina , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frederick K","family":"Korley","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, University of Michigan , Ann Arbor, Michigan , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Larry J","family":"Dumont","sequence":"additional","affiliation":[{"name":"Vitalant Research Institute, Research Department , Denver, Colorado , USA"},{"name":"Department of Pathology, University of Colorado School of Medicine , Aurora, Colorado , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clifton W","family":"Callaway","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, University of Pittsburgh , Pittsburgh, Pennsylvania , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Romina","family":"Libster","sequence":"additional","affiliation":[{"name":"Fundaci\u00f3n INFANT , Buenos Aires , Argentina"},{"name":"Department of Pediatrics, Vanderbilt University School of Medicine , Nashville, Tennessee , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gonzalo Perez","family":"Marc","sequence":"additional","affiliation":[{"name":"Fundaci\u00f3n INFANT , Buenos Aires , Argentina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diego","family":"Wappner","sequence":"additional","affiliation":[{"name":"Fundaci\u00f3n INFANT , Buenos Aires , Argentina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ignacio","family":"Esteban","sequence":"additional","affiliation":[{"name":"Fundaci\u00f3n INFANT , Buenos Aires , Argentina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"Polack","sequence":"additional","affiliation":[{"name":"Fundaci\u00f3n INFANT , Buenos Aires , Argentina"},{"name":"Department of Pediatrics, Vanderbilt University School of Medicine , Nashville, Tennessee , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David J","family":"Sullivan","sequence":"additional","affiliation":[{"name":"Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health , Baltimore, Maryland , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,2,21]]},"reference":[{"key":"2023061611271497300_ciad088-B1","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/S0140-6736(21)02796-3","article-title":"Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020\u201321","volume":"399","author":"COVID-19 Excess Mortality Collaborators","year":"2022","journal-title":"Lancet"},{"key":"2023061611271497300_ciad088-B2","article-title":"Associations between SARS-CoV-2 variants and risk of COVID-19 hospitalization among confirmed cases in Washington state: a retrospective cohort study","author":"Paredes","year":"2022","journal-title":"medRxiv [Preprint]. Posted online 16 February"},{"key":"2023061611271497300_ciad088-B3","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1080\/14760584.2021.1886931","article-title":"Improving pandemic preparedness through better, faster influenza vaccines","volume":"20","author":"Newland","year":"2021","journal-title":"Expert Rev Vaccines"},{"key":"2023061611271497300_ciad088-B4","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijdrr.2022.103074","article-title":"Are preparedness indices reflective of pandemic preparedness? A COVID-19 reality check","volume":"77","author":"Kachali","year":"2022","journal-title":"Int J Disaster Risk Reduct"},{"key":"2023061611271497300_ciad088-B5","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.34233","article-title":"Access to COVID-19 vaccines in high-, middle-, and low-income countries hosting clinical trials","volume":"4","author":"Ramachandran","year":"2021","journal-title":"JAMA Netw Open"},{"key":"2023061611271497300_ciad088-B6","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1001\/jama.2020.4783","article-title":"Treatment of 5 critically ill patients with COVID-19 with convalescent plasma","volume":"323","author":"Shen","year":"2020","journal-title":"JAMA"},{"key":"2023061611271497300_ciad088-B7","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1016\/j.ajpath.2020.08.001","article-title":"Treatment of coronavirus disease 2019 patients with convalescent plasma reveals a signal of significantly decreased mortality","volume":"190","author":"Salazar","year":"2020","journal-title":"Am J Pathol"},{"key":"2023061611271497300_ciad088-B8","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1056\/NEJMoa2029849","article-title":"SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19","volume":"384","author":"Chen","year":"2021","journal-title":"N Engl J Med"},{"key":"2023061611271497300_ciad088-B9","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJMoa2035002","article-title":"REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19","volume":"384","author":"Weinreich","year":"2021","journal-title":"N Engl J Med"},{"key":"2023061611271497300_ciad088-B10","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"key":"2023061611271497300_ciad088-B11","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1056\/NEJMoa2028436","article-title":"Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults","volume":"383","author":"Anderson","year":"2020","journal-title":"N Engl J Med"},{"key":"2023061611271497300_ciad088-B12","author":"World Health Organization (WHO)","year":"2020"},{"key":"2023061611271497300_ciad088-B13","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1056\/NEJMoa2118542","article-title":"Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19","volume":"386","author":"Hammond","year":"2022","journal-title":"N Engl J Med"},{"key":"2023061611271497300_ciad088-B14","doi-asserted-by":"crossref","first-page":"o1282","DOI":"10.1136\/bmj.o1282","article-title":"The black market for covid-19 antiviral drugs","volume":"377","author":"Plata","year":"2022","journal-title":"BMJ"},{"key":"2023061611271497300_ciad088-B15","article-title":"Prices versus costs of production for molnupiravir as a COVID-19 treatment","author":"Hill","year":"2021","journal-title":"Research Square [Preprint]. Posted online 15 December"},{"key":"2023061611271497300_ciad088-B16","doi-asserted-by":"crossref","first-page":"e507","DOI":"10.1093\/cid\/ciac601","article-title":"Sotrovimab resistance and viral persistence after treatment of immunocompromised patients infected with the SARS-CoV-2 Omicron variant","volume":"76","author":"Huygens","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2023061611271497300_ciad088-B17","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1001\/jama.2022.13854","article-title":"Development of resistance-associated mutations after sotrovimab administration in high-risk individuals infected with the SARS-CoV-2 Omicron variant","volume":"328","author":"Birnie","year":"2022","journal-title":"JAMA"},{"key":"2023061611271497300_ciad088-B18","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/j.amjmed.2022.06.019","article-title":"Beneficial and harmful effects of monoclonal antibodies for the treatment and prophylaxis of COVID-19: a systematic review and meta-analysis of randomized controlled trials","volume":"135","author":"Hernandez","year":"2022","journal-title":"Am J Med"},{"key":"2023061611271497300_ciad088-B19","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.cell.2022.12.018","article-title":"Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants","volume":"186","author":"Wang","year":"2023","journal-title":"Cell"},{"key":"2023061611271497300_ciad088-B20","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S1473-3099(22)00733-2","article-title":"Omicron sublineage BQ.1.1 resistance to monoclonal antibodies","volume":"23","author":"Arora","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"2023061611271497300_ciad088-B21","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1038\/s41467-023-36561-6","article-title":"Resistance of Omicron subvariants BA.2.75.2, BA.4.6 and BQ.1.1 to neutralizing antibodies","volume":"14","author":"Planas","year":"2023","journal-title":"Nat Commun"},{"key":"2023061611271497300_ciad088-B22","doi-asserted-by":"crossref","first-page":"e172","DOI":"10.1093\/cid\/ciac571","article-title":"Clinical characteristics and outcome of immunocompromised patients with COVID-19 caused by the Omicron variant: a prospective observational study","volume":"76","author":"Malahe","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2023061611271497300_ciad088-B23","author":"Bhimraj"},{"key":"2023061611271497300_ciad088-B24","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2023061611271497300_ciad088-B25","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.7326\/M20-5261","article-title":"The COVID-NMA project: building an evidence ecosystem for the COVID-19 pandemic","volume":"173","author":"Boutron","year":"2020","journal-title":"Ann Intern Med"},{"key":"2023061611271497300_ciad088-B26","article-title":"RCT studies on preventive measures and treatments for COVID-19","author":"Nguyen","year":"2020","journal-title":"Zenodo [Preprint]. Posted online 1 April"},{"key":"2023061611271497300_ciad088-B27","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1056\/NEJMoa2119657","article-title":"Early outpatient treatment for Covid-19 with convalescent plasma","volume":"386","author":"Sullivan","year":"2022","journal-title":"N Engl J Med"},{"key":"2023061611271497300_ciad088-B28","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1056\/NEJMoa2103784","article-title":"Early convalescent plasma for high-risk outpatients with Covid-19","volume":"385","author":"Korley","year":"2021","journal-title":"N Engl J Med"},{"key":"2023061611271497300_ciad088-B29","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.cmi.2022.08.005","article-title":"Outpatient convalescent plasma therapy for high-risk patients with early COVID-19. A randomized placebo-controlled trial","volume":"29","author":"Gharbharan","year":"2023","journal-title":"Clin Microbiol Infect"},{"key":"2023061611271497300_ciad088-B30","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/S2213-2600(21)00545-2","article-title":"High-titre methylene blue-treated convalescent plasma as an early treatment for outpatients with COVID-19: a randomised, placebo-controlled trial","volume":"10","author":"Alemany","year":"2022","journal-title":"Lancet Respir Med"},{"key":"2023061611271497300_ciad088-B31","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMoa2033700","article-title":"Early high-titer plasma therapy to prevent severe covid-19 in older adults","volume":"384","author":"Libster","year":"2021","journal-title":"N Engl J Med"},{"key":"2023061611271497300_ciad088-B32","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1093\/cid\/ciab579","article-title":"Neutralizing monoclonal antibody treatment reduces hospitalization for mild and moderate coronavirus disease 2019 (COVID-19): a real-world experience","volume":"74","author":"Verderese","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2023061611271497300_ciad088-B33","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1093\/cid\/ciab522","article-title":"Early monoclonal antibody administration can reduce both hospitalizations and mortality in high-risk outpatients with coronavirus disease 2019 (COVID-19)","volume":"74","author":"Jenks","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2023061611271497300_ciad088-B34","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1056\/NEJMoa2116044","article-title":"Molnupiravir for oral treatment of covid-19 in nonhospitalized patients","volume":"386","author":"Jayk Bernal","year":"2022","journal-title":"N Engl J Med"},{"key":"2023061611271497300_ciad088-B35","doi-asserted-by":"crossref","first-page":"371","DOI":"10.4049\/jimmunol.35.5.371","article-title":"Photodynamic action of methylene blue on diphtheric antitoxin","volume":"35","author":"Ross","year":"1938","journal-title":"J Immunol"},{"key":"2023061611271497300_ciad088-B36","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.cmi.2022.01.026","article-title":"Evidence-based dosing of convalescent plasma for COVID-19 in future trials","volume":"28","author":"Rijnders","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"2023061611271497300_ciad088-B37","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1111\/trf.16871","article-title":"How do I implement an outpatient program for the administration of convalescent plasma for COVID-19?","volume":"62","author":"Bloch","year":"2022","journal-title":"Transfusion"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciad088\/49677718\/ciad088.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/76\/12\/2077\/50626501\/ciad088.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/76\/12\/2077\/50626501\/ciad088.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T07:29:17Z","timestamp":1686900557000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/76\/12\/2077\/7048396"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,21]]},"references-count":37,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2023,2,21]]},"published-print":{"date-parts":[[2023,6,16]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciad088","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2022.12.16.22283585","asserted-by":"object"}]},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,6,15]]},"published":{"date-parts":[[2023,2,21]]}}}